Fanconi anemia genes and also WRN are subject to another phase 2 trial in germline mutated metastatic BC, where the response of patients with mutations in those genes is compared to the response of patients with mutations in BRCA1/2, PALB2 and CHEK2 in regard to combination therapy of immunotherapeutic agent PD-1 (HX008) and PARPi (niraparib) (NCT04508803). This evidence concerns the gene PALB2 and breast cancer.